Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 1/2023

10-07-2023 | Late Onset Autoimmune Diabetes in Adults | Meta- Analysis

The worldwide prevalence of latent autoimmune diabetes of adults among adult-onset diabetic individuals: a systematic review and meta-analysis

Authors: Deepika Ramu, Selvaraj Ramaswamy, Suresh Rao, Solomon F. D. Paul

Published in: Endocrine | Issue 1/2023

Login to get access

Abstract

Purpose

The actual global burden of Latent Autoimmune Diabetes of Adults (LADA) remains unknown even though its prevalence is almost equal to the type 1 form of diabetes. Hence the present systematic review and meta-analysis were performed to estimate the prevalence of LADA among diabetic individuals using the studies published at global levels.

Methods

A comprehensive literature revival was performed to identify articles on the prevalence of LADA published till 2023. The prevalence estimates were calculated using DerSimonian and Laird random-effects models with a heterogeneity measure by Cochrane Q and I2 statistics. Publication bias was assessed by the Doi plot and Luis Furuya-Kanamori asymmetry index (LFKindex). P < 0.05 was considered statistically significant.

Results

The overall pooled prevalence of LADA obtained from a total of 51,725 diabetic individuals was found to be 8.9% (95%CI 7.5–10.4, P < 0.001) with a prevalence range of 2.3% in to 18.9% in United Arab Emirates and Bahrain respectively. Subgroup analysis of LADA in the context of the IDF geographic regions showed a higher prevalence in North America (13.5%), 9.5% in Middle East and North Africa, 9.4% in Africa, 9.2% in South East Asia, 8.3% in Western Pacific and the lowest prevalence of 7.0% in Europe.

Conclusion

The Meta-analysis revealed a worldwide prevalence of LADA as 8.9%, with the highest prevalence in Bahrain and the lowest in United Arab Emirates. Further, the higher prevalence in some IDF regions and the inconsistent association between socioeconomic status and LADA recommend more research in the future.
Literature
1.
D. Lovic, A. Piperidou, I. Zografou, H. Grassos, A. Pittaras et al. The growing epidemic of diabetes mellitus. Curr. Vasc. Pharm. 18, 104–109 (2020)CrossRef
2.
X. Lin, Y. Xu, X. Pan, J. Xu, Y. Ding et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci. Rep. 10, 1–11. (2020)
3.
4.
M. Hernández, D. Mauricio, Latent autoimmune diabetes in adults: a review of clinically relevant issues. Adv. Exp. Med Biol. 1307, 29–41 (2021)PubMedCrossRef
5.
6.
V. Rajkumar, S.N. Levine, Latent autoimmune diabetes. StatPearls (2022)
7.
A.C. Britten, K. Jones, C. Törn, M. Hillman, B. Ekholm et al. Latent autoimmune diabetes in adults in a South Asian population of the U.K. Diabetes Care 30, 3088–3090 (2007)PubMedCrossRef
8.
E. Maddaloni, C. Moretti, C. Mignogna, R. Buzzetti, Adult-onset autoimmune diabetes in 2020: an update. Maturitas 137, 37–44 (2020)PubMedCrossRef
9.
A. Kumar, A. de Leiva, Latent autoimmune diabetes in adults (LADA) in Asian and European populations. Diabetes Metab. Res. Rev. 33, e2890 (2017)CrossRef
10.
11.
F. Soriguer-Escofet, I. Esteva, G. Rojo-Martinez, S. Ruiz De Adana, M. Catalá et al. Prevalence of latent autoimmune diabetes of adults (LADA) in Southern Spain. Diabetes Res Clin. Pract. 56, 213–220 (2002)PubMedCrossRef
12.
O.O. Adeleye, A.O. Ogbera, O. Fasanmade, O.O. Ogunleye, A.O. Dada et al. Latent autoimmune diabetes mellitus in adults (LADA) and its characteristics in a subset of Nigerians initially managed for type 2 diabetes. Int. Arch. Med. 5, 1–5 (2012)CrossRef
13.
A. Ipadeola, J.O. Adeleye, K.S. Akinlade, Latent autoimmune diabetes amongst adults with type 2 diabetes in a Nigerian tertiary hospital. Prim. Care Diabetes 9, 231–236 (2015)PubMedCrossRef
14.
S. Muazu, I. Okpe, F. Anumah, The prevalence and characteristics of latent autoimmune diabetes in adults subset among type two diabetes mellitus patients in Northern Nigeria. Ann. Afr. Med. 15, 163–170 (2016)PubMedPubMedCentralCrossRef
15.
Y. Liao, Y. Xiang, Z. Zhou, Diagnostic criteria of latent autoimmune diabetes in adults (LADA): A review and reflection. Front Med China 6, 243–247 (2012)CrossRef
16.
H. Takeda, E. Kawasaki, I. Shimizu, E. Konoue, M. Fujiyama et al. Clinical, autoimmune, and genetic characteristics of adult-onset diabetic patients with GAD autoantibodies in Japan (Ehime Study). Diabetes Care 25, 995–1001 (2002)PubMedCrossRef
17.
Y. Hwangbo, J.T. Kim, E.K. Kim, A.R. Khang, T.J. Oh et al. Prevalence and clinical characteristics of recently diagnosed type 2 diabetes patients with positive anti-glutamic acid decarboxylase antibody. Diabetes Metab. J. 36, 136–143 (2012)PubMedPubMedCentralCrossRef
18.
X. Qi, J. Sun, J.J. Wang, P.P. Wang, Z. Xu et al. Prevalence and correlates of latent autoimmune diabetes in adults in Tianjin, China: a population-based cross-sectional study. Diabetes Care 34, 66–70 (2011)PubMedCrossRef
19.
A. Sachan, G. Zaidi, R.P. Sahu, S. Agrawal, P.G. Colman et al. Low prevalence of latent autoimmune diabetes in adults in northern India. Diabet. Med. 32, 810–813 (2015)PubMedCrossRef
20.
P. Katulanda, B. Shine, G.W. Katulanda, A. Silva, E.L. Asfir et al. Diabetes mellitus among young adults in Sri Lanka-role of GAD antibodies in classification and treatment: the Sri Lanka Young Diabetes study. Diabetologia 51, 1368–1374 (2008)PubMedCrossRef
21.
D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, D. Altman et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 8, 336–341 (2009)
22.
D. Hoy, P. Brooks, A. Woolf, F. Blyth, L. March et al. Assessing risk of bias in prevalence studies: Modification of an existing tool and evidence of interrater agreement. J. Clin. Epidemiol. 65, 934–939 (2012)PubMedCrossRef
23.
24.
25.
W.G. Cochran, The combination of estimates from different experiments. Biometrics 10, 101 (1954)CrossRef
26.
L. Furuya-Kanamori, J.J. Barendregt, S.A.R. Doi, A new improved graphical and quantitative method for detecting bias in meta-analysis. Int. J. Evid. Based Health. 16, 195–203 (2018)CrossRef
27.
M. Wroblewski, A. Gottsater, F. Lindgarde, P. Fernlund, G. Sundkvist, Gender, autoantibodies, and obesity in newly diagnosed diabetic patients aged 40-75 years. Diabetes Care 21, 250–255 (1998)PubMedCrossRef
28.
T. Tuomi, Å.L. Carlsson, H. Li, B. Isomaa, A. Miettinen et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48, 150–157 (1999)PubMedCrossRef
29.
E. Bosi, M.P. Garancini, F. Poggiali, E. Bonifacio, G. Gallus, Low prevalence of islet autoimmunity in adult diabetes and low predictive value of islet autoantibodies in the general adult population of northern Italy. Diabetologia 42, 840–844 (1999)PubMedCrossRef
30.
R. Juneja, I.B. Hirsch, R.G. Naik, B.M. Brooks-Worrell, C.J. Greenbaum et al. Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1 1/2 diabetes in patients presenting with type 2 diabetes. Metabolism 50, 1008–1013 (2001)PubMedCrossRef
31.
V. Tica, M.W. Hanif, A. Andersson, G. Valsamakis, A.H. Barnett et al. Frequency of latent autoimmune diabetes in adults in Asian patients diagnosed as type 2 diabetes in Birmingham, United Kingdom. Ann. N.Y. Acad. Sci. 1005, 356–358 (2003)PubMedCrossRef
32.
L.H. Damanhouri, J.A. Dromey, M.R. Christie, H.A. Nasrat, M.S.M. Ardawi et al. Autoantibodies to GAD and IA-2 in Saudi Arabian diabetic patients. Diabet. Med. 22, 448–452 (2005)PubMedCrossRef
33.
B. Zinman, S.E. Kahn, S.H. Haffner, M.C. O’Neill, M.A. Heise et al. Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes 53, 3193–3200 (2004)PubMedCrossRef
34.
A.G. Unnikrishnan, S.K. Singh, C.B. Sanjeevi, Prevalence of GAD65 antibodies in lean subjects with type 2 diabetes. Ann. N.Y. Acad. Sci. 1037, 118–121 (2004)PubMedCrossRef
35.
E. Arikan, T. Sabuncu, E.M. Ozer, H. Hatemi, The clinical characteristics of latent autoimmune diabetes in adults and its relation with chronic complications in metabolically poor controlled Turkish patients with Type 2 diabetes mellitus. J. Diabetes Complic. 19, 254–258 (2005)CrossRef
36.
S. Genovese, E. Bazzigaluppi, D. Gonçalves, A. Ciucci, M.G. Cavallo et al. Clinical phenotype and β-cell autoimmunity in Italian patients with adult-onset diabetes. Eur. J. Endocrinol. 154, 441–447 (2006)PubMedCrossRef
37.
T.E.H. Römkens, G.C.M. Kusters, M.G. Netea, P.M. Netten, Prevalence and clinical characteristics of insulin-treated, anti-GAD-positive, type 2 diabetic subjects in an outpatient clinical department of a Dutch teaching hospital. Neth. J. Med. 64, 114–118 (2006)PubMed
38.
C.S. Kim, J.H. Nam, J.S. Nam, J.S. Park, E.S. Kang et al. Clinical and biochemical characteristics of nonobese type 2 diabetic patients with glutamic acid decarboxylase antibody in Korea. Metabolism 55, 1107–1112 (2006)PubMedCrossRef
39.
C.F. Otieno, A.N. Huho, E.O. Omonge, A.A. Amayo, E. Njagi, Type 2 diabetes mellitus: clinical and aetiologic types, therapy and quality of glycaemic control of ambulatory patients. East Afr. Med. J. 85, 24–29 (2008)PubMedCrossRef
40.
S.H. Lee, H.S. Kwon, S.J. Yoo, Y.B. Ahn, K.H. Yoon et al. Identifying latent autoimmune diabetes in adults in Korea: the role of C-peptide and metabolic syndrome. Diabetes Res Clin. Pract. 83, 2007–2010 (2009)CrossRef
41.
B. Szepietowska, A. Głȩbocka, U. Puch, M. Górska, M. Szelachowska, Latent autoimmune diabetes in adults in a population-based cohort of Polish patients with newly diagnosed diabetes mellitus. Arch. Med. Sci. 8, 491–495 (2012)PubMedPubMedCentralCrossRef
42.
M. Jasem, A. Al-ubaidi, A. Admon, K. Zwaer, Prevalence of (Lada) among clinically diagnosed type 2 diabetic patients. Med. J. Islamic World Acad. Sci. 18, 49–54 (2010)
43.
G.M. Hossein, S. Maryam, E. Saeed, N. Hamid, M. Mahdieh, The prevalence of latent autoimmune diabetes in adults and its correlates in patients with type 2 diabetes in Kerman, Iran [2011]. Diabetes Metab. Syndrome Clin. Res. Rev. 9, 104–107 (2015)CrossRef
44.
F. Liu, J. Liu, T.S. Zheng, Q. Li, C. Wang et al. The -1123G>C variant of PTPN22 gene promoter is associated with latent autoimmune diabetes in adult Chinese Hans. Cell Biochem Biophys. 62, 273–279 (2012)PubMedCrossRef
45.
Y. Park, S. Hong, L. Park, J. Woo, S. Baik et al. LADA prevalence estimation and insulin dependency during follow-up. Diabetes Metab. Res Rev. 27, 975–979 (2011)PubMedCrossRef
46.
P.P. Brahmkshatriya, A.A. Mehta, B.D. Saboo, R.K. Goyal, P.B. Priyanka, A.M. Anita, D.S. Banshi and R.K. Goyal, Characteristics and prevalence of latent autoimmune diabetes in adults (LADA). ISRN Pharmacol. 2012: 1–8 (2012)
47.
S. Zhang, Q. Sun, K. Feng, Y. Fu, O. Wang et al. Clinical, biochemical, and immunological characteristics of newly diagnosed nonobese diabetic patients aged 18-45 years in China. J. Diabetes Complic. 26, 40–43 (2012)CrossRef
48.
M.O. Roh, C.H. Jung, B.Y. Kim, J.O. Mok, C.H. Kim, The prevalence and characteristics of latent autoimmune diabetes in adults (LADA) and its relation with chronic complications in a clinical department of a university hospital in Korea. Acta Diabetol. 50, 129–134 (2013)PubMedCrossRef
49.
Z. Zhou, Y. Xiang, L. Ji, W. Jia, G. Ning et al. Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China Study): a nationwide, multicenter, clinic-based cross-sectional study. Diabetes 62, 543–550 (2013)PubMedPubMedCentralCrossRef
50.
S.A. Khudhair, Detection of latent autoimmune diabetes of adults among type 2 diabetic patients using glutamic acid decarboxylase antibodies. Med. J. Babylon. 10, 502–507 (2013)
51.
R. Chandni, B.J. Paul, V. Udayabhaskaran, K.P. Ramamoorthy, A study of non-obese diabetes mellitus in adults in a tertiary care hospital in Kerala, India. Int. J. Diabetes Dev. Ctries 33, 83–85 (2013)CrossRef
52.
M.I. Hawa, H. Kolb, N. Schloot, H. Beyan, S.A. Paschou et al. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: action LADA 7. Diabetes Care 36, 908–913 (2013)PubMedPubMedCentralCrossRef
53.
E. Maddaloni, N. Lessan, A. Al Tikriti, R. Buzzetti, P. Pozzilli et al. Latent autoimmune diabetes in adults in the United Arab Emirates: clinical features and factors related to insulin-requirement. PLoS One 10, 4–13 (2015)CrossRef
54.
A. Manofaly, M.I. Gadalla, S.A. Medani, H.M. Abdelrahim, A. Bolad, Diagnosis of autoimmune diabetes in adults using Immunological methods in Khartoum-Sudan. Basic Res. J. 4, 135–139 (2015)
55.
S.M.J. Al-Hasnawi, S.A. Al-Jiboury, Prevalence of latent autoimmune diabetes of adult (LADA) among type 2 diabetes mellitus (DM 2) in Karbala. kufa J. Nurs. Sci. 5, 85–93 (2015)CrossRef
56.
A.I. Ghanem, A.A. Bassyouni, G.A. Omar, Glutamic acid decarboxylase auto-antibodies prevalence among patients with type 2 diabetes mellitus and their clinical characteristics in a sample of the Egyptian population. J. Med. Sci. Res. 2, 257 (2019)
57.
X. Gao, W. Sun, Y. Wang, Y. Zhang, R. Li et al. Prevalence of positive islet autoantibody in type 2 diabetes patients: a cross-sectional study in a Chinese community. Endocr. Connect. 8, 1493–1502 (2019)PubMedPubMedCentralCrossRef
58.
A.A. Tam, D. Ozdemir, N. Bestepe, F.D. Dellal, M.C. Bilginer et al. Low rate of latent autoimmune diabetes in adults (LADA) in patients followed for type 2 diabetes: a single center’s experience in Turkey. Arch. Endocrinol. Metab. 64, 584–590 (2020)PubMedCentral
59.
T. Al-Zubairi, M. Al-Habori, R. Saif-Ali, Latent autoimmune diabetes in adults (Lada) and its metabolic characteristics among yemeni type 2 diabetes mellitus patients. Diabetes Metab. Syndr. Obes. 14, 4223–4232 (2021)PubMedPubMedCentralCrossRef
60.
R. Turner, I. Stratton, V. Horton, S. Manley, P. Zimmet et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 350, 1288–1293 (1997)PubMedCrossRef
61.
A. Kumar, A. de Leiva, Latent autoimmune diabetes in adults in north indian region: assessment of β-cell function, metabolic and immunological features. Metab. Syndr. Relat. Disord. 15, 494–499 (2017)PubMedCrossRef
62.
A.M. Manisha, A.R. Shangali, S.G. Mfinanga, E.V. Mbugi, Prevalence and factors associated with latent autoimmune diabetes in adults (LADA): a cross-sectional study. BMC Endocr. Disord. 22, 175 (2022)PubMedPubMedCentralCrossRef
63.
G.A. Nolasco-Rosales, D. Ramírez-González, E. Rodríguez-Sánchez, Á. Ávila-Fernandez, G.E. Villar-Juarez et al. Identification and phenotypic characterization of patients with LADA in a population of southeast Mexico. Sci. Rep. 13, 7029 (2023)PubMedPubMedCentralCrossRef
64.
R. Buzzetti, S. Di Pietro, A. Giaccari, A. Petrone, M. Locatelli et al. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care 30, 932–938 (2007)PubMedCrossRef
65.
E.T. Zaharieva, T.V. Velikova, A.D. Tsakova, Z.A. Kamenov, Prevalence of Positive Diabetes-Associated Autoantibodies among Type 2 Diabetes and Related Metabolic and Inflammatory Differences in a Sample of the Bulgarian Population. J. Diabetes Res. 2017, 1–6 (2017)CrossRef
66.
B. Zhou, Y. Lu, K. Hajifathalian, J. Bentham, M. Di Cesare et al. Worldwide trends in diabetes since 1980: A pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 387, 1513–1530 (2016)CrossRef
67.
A. Nordström, J. Hadrévi, T. Olsson, P.W. Franks, P. Nordström, Higher prevalence of type 2 diabetes in men than in women is associated with differences in visceral fat mass. J. Clin. Endocrinol. Metab. 101, 3740–3746 (2016)PubMedCrossRef
68.
C. Mapa-Tassou, J.-C. Katte, C. Mba Maadjhou, J.C. Mbanya, Economic impact of diabetes in Africa. Curr. Diab Rep. 19, 5 (2019)PubMedCrossRef
69.
K. Ogurtsova, L. Guariguata, N.C. Barengo, P.L.-D. Ruiz, J.W. Sacre et al. IDF diabetes Atlas: global estimates of undiagnosed diabetes in adults for 2021. Diabetes Res Clin. Pract. 183, 109118 (2022)PubMedCrossRef
70.
H. Sun, P. Saeedi, S. Karuranga, M. Pinkepank, K. Ogurtsova et al. IDF Diabetes Atlas: Global regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin. Pract. 183, 109119 (2022)PubMedCrossRef
71.
V. Mohan, R. Pradeepa, Lessons from prevention and control of type 2 diabetes in india for other noncommunicable diseases in South-East Asia region. WHO South East Asia J. Public Health 11, 67–70 (2022)PubMed
72.
V. Mohan, V. Ruchi, R. Gayathri, M. Bai, V. Sudha et al. Slowing the diabetes epidemic in the World Health Organization South-East Asia Region: the role of diet and physical activity. WHO South East Asia J. Public Health 5, 5 (2016)PubMedCrossRef
73.
M. Abu-Farha, J. Tuomilehto, J. Abubaker, Editorial: Diabetes in the Middle East. Front. Endocrinol. 12 (2021)
74.
S. Tatulashvili, G. Fagherazzi, C. Dow, R. Cohen, S. Fosse et al. Socioeconomic inequalities and type 2 diabetes complications: a systematic review. Diabetes Metab. 46, 89–99 (2020)PubMedCrossRef
75.
S. Carlsson, K.G.V. Midthjell, Influence of family history of diabetes on incidence and prevalence of latent results from the Nord-Trondelag health study. Community Med. 30, 3040–5 (2007)
76.
R. Buzzetti, C.C. Quattrocchi, L. Nisticò, Dissecting the genetics of type 1 diabetes: relevance for familial clustering and differences in incidence. Diabetes Metab. Rev. 14, 111–128 (1998)PubMedCrossRef
Metadata
Title
The worldwide prevalence of latent autoimmune diabetes of adults among adult-onset diabetic individuals: a systematic review and meta-analysis
Authors
Deepika Ramu
Selvaraj Ramaswamy
Suresh Rao
Solomon F. D. Paul
Publication date
10-07-2023
Publisher
Springer US
Published in
Endocrine / Issue 1/2023
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-023-03424-5

Other articles of this Issue 1/2023

Endocrine 1/2023 Go to the issue

Original Article

Alteration of BDNF, SPARC, FGF-21, and GDF-15 circulating levels after 1 year of anti-obesity treatments and their association with 1-year weight loss

Original Article

Effect of a single dose of zoledronic acid on bone mineral density and trabecular bone score in Indian postmenopausal osteoporotic women with and without type 2 diabetes mellitus – A prospective cohort pilot study

Original Article

Obesity and hyperandrogenism are implicated with anxiety, depression and food cravings in women with polycystic ovary syndrome

Review

Endothelium dysfunction and thrombosis in COVID-19 with type 2 diabetes

Original Article

MicroRNA-130a-3p impedes the progression of papillary thyroid carcinoma through downregulation of KPNB1 by targeting PSME3

Brief report

To support the use of NT-proBNP to better detect heart failure in patients with type 2 diabetes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits